iPSirius is creating a new frontier in stem cell-based cancer therapeutics by developing a vaccine to fight aggressive tumors.
Paris, France, 19th December 2022 – iPSirius is a European immunotherapy company that is working to bring a new range of off-the-shelf vaccines to cancer patients worldwide to improve their prognosis and quality of life. iPSirius has developed a pipeline of engineered induced pluripotent stem cell (iPS) vaccines using its proprietary iPVAC technology. [Read more…]